We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Blood Test Could Reveal Alzheimer’s Disease Biology and Risk for Progression

By LabMedica International staff writers
Posted on 20 Sep 2024
Print article
Image: New Alzheimer’s studies have revealed disease biology, risk for progression, and potential for a novel blood test (Photo courtesy of Adobe Stock)
Image: New Alzheimer’s studies have revealed disease biology, risk for progression, and potential for a novel blood test (Photo courtesy of Adobe Stock)

The inability to diagnose Alzheimer’s disease, the most prevalent form of dementia in the elderly, at an early stage of molecular pathology is considered a key reason why treatments fail in clinical trials. Previous efforts to diagnose Alzheimer’s molecularly have focused on the central biomarkers of β-amyloid, Tau, and Neurodegeneration (A/T/N), which are measured through the analysis of proteins associated with neurodegeneration. A/T/N can be assessed in brain tissue, through in vivo brain imaging techniques, and by analyzing cerebrospinal fluid and plasma. Alzheimer’s disease is believed to be triggered by a combination of genetic and environmental risk factors. Blood-based biomarkers, such as plasma microRNAs (miRNAs)—molecules that regulate interactions between the genome and the environment and control the expression of genes governing brain functions that deteriorate in Alzheimer’s—could offer advantages in terms of cost-effectiveness, accessibility, and reduced invasiveness.

Two new papers by a research team, including investigators from Boston University (Boston, MA, USA), have demonstrated that evaluating microRNAs in blood can be used not only to diagnose mild cognitive impairment (MCI) but also, crucially, to predict the progression from MCI to dementia due to Alzheimer’s disease. Additionally, the researchers identified microRNA candidate molecular biomarkers associated with the current A/T/N Alzheimer’s biomarkers. In their study, the team analyzed miRNA expression in plasma samples from three groups of participants—those who were cognitively normal, those with mild cognitive impairment, and those with dementia due to Alzheimer’s disease. They discovered that, when combined with neuropsychological testing, plasma microRNAome evaluation could help predict which aging individuals concerned about cognitive decline are likely to develop Alzheimer’s.

Although novel therapies for Alzheimer’s disease are beginning to enter clinical care, the researchers emphasize that these treatments will only be effective if patients at risk are identified as early as possible. The researchers highlight the need for improved tools for early detection of Alzheimer’s, which are essential for developing prevention and treatment strategies for a disease that causes significant suffering and places a heavy burden on healthcare systems worldwide. These findings are published in Alzheimer’s & Dementia.

“Our papers are the result of a successful collaboration that tied the technology developed by professor Andre Fischer in Germany’s DZNE to reliably measure the levels of microRNA in human plasma, and the power of blood samples obtained from hundreds of ADNI participants participating in a simulated clinical trial taking place at about 60 medical centers across the US and Canada,” explained one of four senior authors Ivana Delalle, MD, PhD, professor of pathology & laboratory medicine at Boston University Chobanian & Avedisian School of Medicine. “Our discovery is important because, unlike the current A/T/N biomarkers, microRNAs may serve as blood molecular biomarkers years before Alzheimer’s disease manifests clinically, thus identifying the time window for effective prevention or early intervention to stop the progression of Alzheimer’s.”

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Cooling Table Centrifuge
MPW-352R
New
Dengue Test
Lab Rapid Dengue NS1

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.